Abstract:ID 92269 Poster Board 517 The opioid crisis (e.g., overdose deaths) has worsened significantly during the COVID-19 pandemic, despite a decrease in the number of prescriptions for opioids. However, the number of prescriptions for and the off-label use of gabapentinoids (gabapentin and pregabalin) as alternative medications used for chronic pain is soaring with gabapentinoids increasingly detected in opioid overdose victims, raising serious concerns about the health risks of this class of drugs. The effect of gabapentinoids on mu opioid receptor (MOR)-mediated in vivo activity is not well characterized, although a study in male rats reported that gabapentinoids decrease the potency of the opioid receptor antagonist naloxone to reverse hypoventilation by the morphinan MOR agonist heroin. Male rats (n = 8) discriminating the non-morphinan MOR agonist fentanyl (0.0032 mg/kg, intraperitoneally, i.p.) from saline under a fixed-ratio 10 schedule of food reinforcement, were used to test the following hypotheses: 1) gabapentinoids do not share discriminative stimulus effects with fentanyl; 2) gabapentinoids increase the potency of fentanyl to produce discriminative stimulus effects; and 3) gabapentinoids decrease the potency of naloxone to antagonize the discriminative stimulus effect of fentanyl. Gabapentin (10-320 mg/kg, i.p.) and pregabalin (3.2-100 mg/kg, i.p.) occasioned a maximum average, respectively, of 37.8% and 46.3% fentanyl-appropriate responding, and decreased rates of responding to 6.0% and 7.4% of control. Heroin (0.032-0.1 mg/kg, i.p.) occasioned 100% fentanyl-appropriate responding whereas the stimulant drugs cocaine (0.32-10 mg/kg, i.p.) and d -methamphetamine (0.1-3.2 mg/kg, i.p.) did not increase fentanyl-appropriate responding up to doses that significantly decreased rates of responding. Acute pretreatment with gabapentin (3.2-32 mg/kg, i.p.) or pregabalin (3.2-32 mg/kg, i.p.) dose-dependently shifted the fentanyl discrimination dose-effect function up to 17-fold to the left. In contrast, naloxone (0.01-1.0 mg/kg, i.p.) dose-dependently shifted the fentanyl discrimination dose-effect function up to 95-fold to the right. Rightward shifts by naloxone (0.1 and 1.0 mg/kg, i.p.) in the fentanyl discrimination dose-effect function were attenuated dose-dependently by gabapentin (3.2-100 mg/kg, i.p.) and pregabalin (3.2-100 mg/kg, i.p.) up to 63 fold. Similar presession treatment effects of gabapentinoids were observed with heroin. These results suggest that gabapentinoids 1) produce only partial but significant fentanyl-like discriminative stimulus effects, 2) enhance the discriminative stimulus effects of the MOR agonists including the non-morphinan (phenylpiperidine) fentanyl as well as the morphinan heroin, and 3) attenuate naloxone antagonism of the discriminative stimulus effects of the MOR agonists. These results can help guide government agencies and others develop better policies for regulating gabapentinoids and treating opioid misuse and overdose. Supported by USPHS grant R01DA058018 and the Welch Foundation (Grant AQ-0039).

Lipophilic analogues of D-cysteine prevent and reverse physical dependence to fentanyl in male rats

L-cysteine ethyl ester prevents and reverses acquired physical dependence on morphine in male Sprague Dawley rats

The cell-permeant antioxidant D-thiol ester D-cysteine ethyl ester overcomes physical dependence to morphine in male Sprague Dawley rats

L-NAC and L-NAC methyl ester prevent and overcome physical dependence to fentanyl in male rats

The epigenetic signatures of opioid addiction and physical dependence are prevented by D-cysteine ethyl ester and betaine

Fentanyl-induced reward seeking is sex and dose dependent and is prevented by D-cysteine ethylester

D-Cysteine Ethyl Ester Reverses the Deleterious Effects of Morphine on Breathing and Arterial Blood–Gas Chemistry in Freely-Moving Rats

Cannabidiol reverses fentanyl-induced addiction and modulates neuroinflammation

Evaluating the rate of reversal of fentanyl-induced respiratory depression using a novel long-acting naloxone nanoparticle, cNLX-NP

Effects of Fentanyl Dose and Exposure Duration on the Affective and Somatic Signs of Fentanyl Withdrawal in Rats.

The ventilatory depressant actions but not the antinociceptive effects of morphine are blunted in rats receiving intravenous infusion of L-cysteine ethyl ester

Effects of xylazine on naloxone-precipitated fentanyl withdrawal in male and female rats

L-cysteine ethylester reverses the adverse effects of morphine on breathing and arterial blood-gas chemistry while minimally affecting antinociception in unanesthetized rats

Oral Fentanyl Consumption Alters Sleep Rhythms, Promotes Avoidance Behaviors, Impairs Fear Extinction Learning, and Alters Basolateral Amygdala Physiology in Male and Female Mice

Ampakine CX717 Protects Against Fentanyl-induced Respiratory Depression and Lethal Apnea in Rats

Biological sex modulates the efficacy of 2,5-dimethoxy-4-iodoamphetamine (DOI) to mitigate fentanyl demand

Naloxone’s Dose-Dependent Displacement of [11c]carfentanil and Duration of Receptor Occupancy in the Rat Brain

Effects of gabapentinoids in male rats discriminating fentanyl from saline

D‐cycloserine facilitates extinction of cocaine self‐administration in rats

Novel synthetic opioids produce potent morphine‐like discriminative stimulus effects in rats

Dezocine Alleviates Morphine-Induced Dependence in Rats